Effects of dienogest on surgically induced endometriosis in rats after repeated oral administration

Gynecologic and Obstetric Investigation

Volumn 72, Issue 3, 2011, Pages 145-151

  Fischer, O M ^a   Kaufmann Reiche, U ^a   Moeller, C ^a   Fuhrmann, U ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Danazol; Dienogest; Endometriosis; Progestins; Rat model in vivo

Indexed keywords

DANAZOL; DIENOGEST; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOTRANSPLANTATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; ENDOMETRIOSIS; FEMALE; LAPAROTOMY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS; UTERUS WEIGHT;

ANIMALS; DANAZOL; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HORMONE ANTAGONISTS; NANDROLONE; OVARY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TREATMENT OUTCOME; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80255135558     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000331642     Document Type: Article

References (38)

1. Kennedy S, Bergqvist A, Chapron C, et al; ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group: ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698-2704.
2. Sinaii N, Cleary SD, Younes N, et al: Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience. Fertil Steril 2007; 87: 1277-1286. (Pubitemid 46839103)
3. Gao X, Yeh YC, Outley J, et al: Health-related quality of life burden of women with endometriosis: a literature review. Curr Med Res Opin 2006; 22: 1787-1797. (Pubitemid 44449235)
4. Kitawaki J, Kado N, Ishihara H, et al: Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002; 83: 149-155. (Pubitemid 37040651)
5. Prentice A, Deary AJ, Bland E, et al: Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev, 2000; 2:CD002122.
6. Prentice A, Deary AJ, Goldbeck-Wood S, et al: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2000; 2:CD000346.
7. Jackson B, Telner DE: Managing the misplaced: approach to endometriosis. Can Fam Phys 2006; 52: 1420-1424. (Pubitemid 44916991)
8. Sagsveen M, Farmer JE, Prentice A, Breeze A: Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; 4:CD001297.
9. Barbieri RL, Ryan KJ: Danazol: endocrine pharmacology and therapeutic application. Am J Obstet Gynec 1981; 141: 453-463. (Pubitemid 11027006)
10. Alvarado RG, Liu JY, Zwolak RM: Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg 2001; 34: 1123-1126. (Pubitemid 33660677)
11. Bartley J, Loddenkemper C, Lange J, et al: Hepatocellular adenoma and focal nodular hyperplasia after long-term use of danazol for endometriosis: a case report. Arch Gynecol Obstet 2004; 269: 290-293. (Pubitemid 38661272)
12. Beaumont H, Augood C, Duckitt K, Lethaby A: Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2007; 3:CD001017.
13. Vercellini P, Fedele L, Pietropaolo G, et al: Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003; 9: 387-396. (Pubitemid 36987285)
14. Moghissi AS: Treatment of endometriosis with estrogen-progestin combination and with progestogens alone. Clin Obstet Gynecol 1988; 31: 823-828.
15. Schlaff WD, Carson SA, Luciano A, et al: Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85: 314-325. (Pubitemid 43170902)
16. Crosignani PG, Luciano A, Ray A, Bergqvist A: Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21: 248-256. (Pubitemid 41794318)
17. Ishida Y, Mine T, Taguchi T: Effect of progestins with different glucocorticoid activity on bone metabolism. Clin Endocrinol (Oxf) 2008; 68: 423-428. (Pubitemid 351257862)
18. Oettel M, Breitbarth H, Elger W, et al. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care 1999; 4(suppl 1):2-13.
19. Kuhl H: Comparative pharmacology of newer progestogens. Drugs 1996; 51: 188-215. (Pubitemid 26039155)
20. Katsuki Y, Sasagawa S, Takano Y, et al: Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid. Drugs Exp Clin Res 1997; 23: 45-62. (Pubitemid 28461325)
21. Sasagawa S, Shimizu Y, Kami H, et al: Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008; 73: 222-231.
22. Köhler G, Faustmann TA, Gerlinger C, et al: A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010; 108: 21-25.
23. Strowitzki T, Faustmann T, Gerlinger C, Seitz C: Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010; 151: 193-198.
24. Strowitzki T, Marr J, Gerlinger C, et al: Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010; 25: 633-641.
25. Seitz C, Gerlinger C, Faustmann T, Strowitzki T: Safety of dienogest in the long-term treatment of endometriosis: a one-year, open-label, follow-up study. American Society for Reproductive Medicine, 65th Annual Meeting, Atlanta, Oct 17-21, 2009.
26. Nakamura M, Katsuki Y, Shibutani Y, Oikawa T: Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 1999; 386: 33-40. (Pubitemid 30009620)
27. Katayama H, Katayama T, Uematsu K, et al: Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod 2010; 25: 2851-2858.
28. Okada H, Nakajima T, Yoshimura T, et al: The inhibitory effects of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod 2001; 7: 341-347. (Pubitemid 32288323)
29. Horie S, Harada T, Mitsunari M, et al: Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril 2005; 83: 1530-1535. (Pubitemid 40615830)
30. Fu L, Osuga Y, Morimoto C, et al: Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells. Fertil Steril 2008; 89: 1344-1347. (Pubitemid 351680084)
31. Shimizu Y, Takeuchi T, Mita S, et al: Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 2009; 15: 693-701.
32. Katsuki Y, Takano Y, Futamura Y, et al: Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol 1998; 138: 216-226. (Pubitemid 28131102)
33. Vernon MW, Wilson EA: Studies on the surgical induction of endometriosis in the rat. Fertil Steril 1985; 44: 684-694. (Pubitemid 16199664)
34. Wright JA, Sharpe-Timms KL: Gonadotropin-releasing hormone agonist therapy reduces postoperative adhesion formation and reformation after adhesiolysis in rat models for adhesion formation and endometriosis. Fertil Steril 1995; 63: 1094-1100.
35. Taylor RN, Lebovic DI, Mueller MD: Angiogenic factors in endometriosis. Ann NY Acad Sci 2002; 955: 89-100. (Pubitemid 34271066)
36. Machado DE, Berardo PT, Palmero CY, Nasciutti LE: Higher expression of vascular endothelial growth factor (VEGF and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J Exp Clin Cancer Res 2010; 29: 4.
37. Grümmer R: Animal models in endometriosis research. Hum Reprod Update 2006; 12: 641-649. (Pubitemid 44288713)
38. Oettel M, Carol W, Elger W, et al: A 19-norprogestin without 17a-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995: 31: 517-536. (Pubitemid 26031142)